FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and is intended for the prevention and treatment of nocturnal acid breakthrough (NAB). Pharmaceutical composition containing the benzimidazole derivative 4-(5,7-difluorochromane-4-yloxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide or its pharmaceutically acceptable salt is used. Unit dosage form containing 50 to 200 mg of 4-(5,7-difluorochromane-4-yloxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide or its pharmaceutically acceptable salt is also disclosed.
EFFECT: group of inventions widens the range of therapeutic agents.
11 cl, 7 tbl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING GASTROINTESTINAL TRACT DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION | 2014 |
|
RU2563993C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE | 2012 |
|
RU2501549C1 |
| PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
| IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2725147C1 |
| TREATMENT OF PHARMACOLOGICALLY INDUCED HYPACIDITY | 2012 |
|
RU2603462C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING A PROTON PUMP INHIBITOR AND ANTACID | 2020 |
|
RU2807610C1 |
| COMPOSITIONS FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) | 2010 |
|
RU2524639C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING RABEPRAZOLE AND METHOD FOR PRODUCING IT | 2014 |
|
RU2554735C1 |
| NOVEL ACID SECRETION INHIBITOR AND ITS USE | 2021 |
|
RU2815697C1 |
| COMPOSITION INHIBITING SECRETION OF ACID IN STOMACH | 2003 |
|
RU2340358C2 |
